探讨 COVID19 恢复期血浆疗效试验的可能性艺术。

The art of the possible in approaching efficacy trials for COVID19 convalescent plasma.

机构信息

North-Western Tuscany Blood Bank, Pisa University Hospital, Pisa, Italy.

Faculty of Medicine and Medical Sciences, The University of Western Australia, Perth, Australia.

出版信息

Int J Infect Dis. 2021 Jan;102:244-246. doi: 10.1016/j.ijid.2020.10.074. Epub 2020 Oct 30.

DOI:10.1016/j.ijid.2020.10.074

PMID:33130197

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7836915/

Abstract

COVID-19 convalescent plasma (CCP) is widely used as a treatment. While safety data are enough, high-level evidences of efficacy are still missing. We summarize here the results from randomized controlled trials (RCT) published to date and analyze their flaws and biases. We then provide suggestions for next round of CCP RCTs, discussing specification of CCP, therapeutic dose, timing, control arm, disease stage, and outcome measures.

摘要

COVID-19 恢复期血浆（CCP）被广泛用作治疗方法。虽然安全性数据充足，但仍缺乏高等级的疗效证据。我们在这里总结了迄今为止发表的随机对照试验（RCT）的结果，并分析了它们的缺陷和偏差。然后，我们为下一轮 CCP RCT 提供了建议，讨论了 CCP 的具体规定、治疗剂量、时机、对照臂、疾病阶段和结果测量。